ADC Therapeutics SA
Pyrrolobenzodiazepine-antibody conjugates
Last updated:
Abstract:
The present disclosure relates to the use of antibody-drug conjugates (ADCs) comprising pyrrolobenzodiazepine (PBD) dimers and anti-CD25 antibodies for use in treating disorders characterized by the presence of CD25+ve cells.
Status:
Grant
Type:
Utility
Filling date:
25 Nov 2015
Issue date:
22 Sep 2020